News from us and our partners

Tags

Topics

0 results

News
17 December, 2024
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
News
12 December, 2024
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines
News
11 December, 2024
Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
News
11 December, 2024
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
News
11 December, 2024
ProQR Therapeutics announces $8.1 million in new funding from Rett Syndrome Research Trust to expand RNA editing collaboration
News
10 December, 2024
ProQR appoints Peter A. Beal, PhD, as Chief ADAR Scientist
News
5 December, 2024
Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease
News
3 December, 2024
AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
News
26 November, 2024
Handbook for impact accountability in VC developed by coalition of impact-driven funds
Feature
26 November, 2024
Impact accountability in venture capital: A ready reference for practitioners
News
19 November, 2024
Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
News
18 November, 2024
Cure51 Launches NHS-Approved Study with Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets
News
18 November, 2024
BrightHeart secures FDA clearance for first AI software revolutionizing prenatal fetal heart ultrasound evaluations
News
14 November, 2024
Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion
News
31 October, 2024
TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative
News
30 October, 2024
Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome

Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines

ProQR Therapeutics announces $8.1 million in new funding from Rett Syndrome Research Trust to expand RNA editing collaboration

ProQR appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Muna Therapeutics Announces Strategic Alliance with GSK to Accelerate Development of Novel Treatments for Alzheimer’s Disease

AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa

Handbook for impact accountability in VC developed by coalition of impact-driven funds

Impact accountability in venture capital: A ready reference for practitioners

Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment

Cure51 Launches NHS-Approved Study with Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets

BrightHeart secures FDA clearance for first AI software revolutionizing prenatal fetal heart ultrasound evaluations

Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion

TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative

Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome